Filing Scope and Business Context
The provided filing is Landec Corporation’s Form 10-K for the fiscal year ended May 27, 2012, not a Lifecore Biomedical standalone filing or a 2011 Q4 filing. Lifecore is a wholly owned Landec subsidiary and operates the Hyaluronan-based Biomaterials segment. Landec’s businesses comprise Food Products Technology, Food Export, Hyaluronan-based Biomaterials and Technology Licensing.
Landec develops and sells Intelimer polymer products, BreatheWay produce-packaging technology, fresh-cut and whole produce, hyaluronan-based medical biomaterials and licensed polymer applications.
Financial Performance and Position
| Metric | Fiscal 2012 | Fiscal 2011 | Change |
|---|---|---|---|
| Total revenue | $317.6 million | $276.7 million | 15% |
| Gross profit | $52.1 million | $46.7 million | 12% |
| Gross margin | 16.4% | 16.9% | Down approximately 50 bps |
| Operating income | $14.6 million | $8.0 million | 81% |
| Net income attributable to common stockholders | $12.7 million | $3.9 million | 224% |
| Diluted EPS | $0.49 | $0.15 | Up $0.34 |
| Operating cash flow | $22.2 million | $14.5 million | 53% |
| Capital expenditures | $5.4 million | $6.7 million | Down 20% |
Segment revenue was $207.6 million for Food Products Technology, $71.5 million for Food Export, $34.3 million for Hyaluronan-based Biomaterials and $4.2 million for Technology Licensing. Lifecore revenue increased 5%, and its gross profit was $18.0 million; management states that Lifecore historically operates at approximately 50% gross margins.
Fiscal 2012 net income benefited from $5.8 million of unrealized fair-value appreciation in the Windset investment, $1.1 million of Windset dividend income and a $4.0 million Monsanto termination fee. These items should be distinguished from recurring operating performance.
Liquidity, Debt and Cash Flow
- Cash and cash equivalents were $22.2 million at May 27, 2012, compared with $8.1 million a year earlier. Marketable securities declined from $28.1 million to zero.
- Operating activities generated $22.2 million; investing activities used $44.1 million, primarily because of the $66.8 million GreenLine acquisition and $5.4 million of capital expenditures; financing activities provided $35.9 million.
- Total debt was $58.98 million, consisting of $47.32 million of long-term debt and $11.67 million drawn under Apio’s revolving credit facility. Current maturities of long-term debt were $7.0 million.
- Apio obtained a $25.0 million asset-based revolving facility, a $12.7 million equipment loan and a $19.1 million real-estate loan in connection with the GreenLine acquisition. Lifecore entered into a $12.0 million term loan and an $8.0 million revolving facility; no amount was drawn on Lifecore’s revolver at year-end.
- Contractual obligations totaled approximately $74.6 million, including $59.0 million of debt principal, $8.4 million of interest, $5.1 million of operating leases, $1.9 million of purchase commitments and $0.2 million of capital leases.
- Management stated that existing cash, marketable securities and operating cash flow were expected to fund operational and capital requirements for at least the next twelve months.
Material Changes Versus the Prior Period
- Apio acquired GreenLine on April 23, 2012 for $66.8 million, including $62.9 million of cash and $3.9 million of estimated contingent consideration. GreenLine contributed $9.1 million of revenue during the post-acquisition period and added $13.2 million of goodwill and $43.5 million of intangible assets.
- Food Products Technology revenue increased 18%, primarily from an 11% increase in unit volumes, expanded distribution, new products and $9.1 million from GreenLine. Gross profit increased 34%.
- Food Export revenue increased 16%, with higher volumes, more favorable pricing and improved product mix.
- Technology Licensing revenue declined 39% following expiration of the Monsanto agreement on December 1, 2011. Monsanto paid a $4.0 million termination fee, and the Intellicoat rights reverted to Landec.
- Operating income improved partly because fiscal 2011 included a $4.8 million goodwill impairment charge, while fiscal 2012 included $1.4 million of GreenLine acquisition-related expenses.
- Landec repurchased and retired 917,244 common shares for approximately $5.0 million during fiscal 2012. Up to $3.8 million remained available under the repurchase authorization.
- Landec paid the $10.0 million Lifecore earn-out on May 29, 2012, based on achievement of contractual revenue targets.
- On June 24, 2012, after the reporting date, Landec sold Landec Ag to INCOTEC for $0.6 million and entered into licensing and polymer supply agreements that provide for future royalties and value-sharing.
Outlook, Commentary and Principal Risks
Management cited growth opportunities from GreenLine integration, expanded club-store and foodservice distribution, new value-added produce products, continued Lifecore customer and application development, and BreatheWay licensing. Windset commercial sales for greenhouse produce were projected to begin in fiscal 2013.
The filing does not provide formal consolidated revenue or earnings guidance. Management expects continued research and development spending and states that future capital needs will depend on product development, acquisitions, commercialization, regulatory requirements, weather, licensing activity and competitive conditions.
- Produce operations are seasonal and exposed to weather, crop availability, commodity prices, perishability and supply-chain disruptions. Fiscal 2011 net income was reduced by approximately $5.0 million by weather-related sourcing problems.
- Customer concentration is significant: the top five customers represented approximately 45% of fiscal 2012 revenue, and the largest Food Products Technology customer represented approximately 17%.
- Approximately 36% of fiscal 2012 revenue came from international customers, creating exposure to foreign regulation, trade restrictions, political conditions and currency-related demand effects.
- Apio and Lifecore depend heavily on concentrated manufacturing locations and several single-source suppliers and service providers.
- Lifecore’s products are subject to FDA and foreign regulatory requirements, including medical-device approvals, quality-system compliance, inspections and potential recalls or restrictions.
- The company carries substantial goodwill and intangible assets. Fiscal 2012 impairment testing indicated no impairment, but valuations depend on projected cash flows, discount rates and other subjective assumptions.
- The Windset investment is a Level 3 fair-value measurement. Changes in projected cash flows, growth rates or discount rates could materially affect reported income.
- Lifecore’s financing requires compliance with minimum fixed-charge coverage, quick-ratio and tangible-net-worth covenants beginning in future periods.
- The filing reports no material litigation as of the filing date, but product liability, environmental, tax, intellectual-property and regulatory contingencies remain relevant risks.
Important Facts for Investors to Verify
- Confirm that the requested period and issuer are correct: the source is Landec’s fiscal 2012 10-K, while the request metadata identifies Lifecore Biomedical and 2011 Q4.
- Assess the recurring earnings contribution of GreenLine separately from acquisition costs, purchase-accounting effects and integration risks.
- Separate recurring operating results from the $5.8 million Windset fair-value gain, $1.1 million dividend income and $4.0 million Monsanto termination fee.
- Review GreenLine’s contingent earn-out exposure, including the recorded $3.9 million liability and potential payments of up to $7.0 million.
- Evaluate debt service, refinancing needs and compliance with Apio and Lifecore financial covenants.
- Examine Lifecore’s customer concentration, regulatory status and supply agreements, including agreements extending through 2014, 2015 and 2017.
- Review assumptions supporting the $49.6 million goodwill balance, $59.0 million of other intangible assets and the $21.5 million fair value assigned to the Windset investment.
- Verify the post-year-end sale of Landec Ag and the expected economic impact of the INCOTEC royalty and supply arrangements.